[
  {
    "ts": null,
    "headline": "What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?",
    "summary": "Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the call, Goldman Sachs has outlined its expectations for the guide and commentary on the upcoming year. The analyst anticipates that Pfizer’s management will guide to EPS in the mid-to-high $2 range with core business growth offset by the $0.30 in favorable but non-recurring items during 2024. Pfizer highlighted several factors affecting its 2024 EPS that won’t carry over to 20",
    "url": "https://finnhub.io/api/news?id=502cff5acd2dd0e1cd89a0d6f8cdca1e2bd2c1ae6f6be62299902380161ffb32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734375220,
      "headline": "What To Expect When Pfizer Outlines Its 2025 Financial Outlook On Tuesday?",
      "id": 132014637,
      "image": "https://media.zenfs.com/en/Benzinga/771d1716015e6efdf318c3d8ed5ce73c",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc. (NYSE:PFE) will conduct an investor call on Tuesday to provide full-year 2025 financial guidance. Ahead of the call, Goldman Sachs has outlined its expectations for the guide and commentary on the upcoming year. The analyst anticipates that Pfizer’s management will guide to EPS in the mid-to-high $2 range with core business growth offset by the $0.30 in favorable but non-recurring items during 2024. Pfizer highlighted several factors affecting its 2024 EPS that won’t carry over to 20",
      "url": "https://finnhub.io/api/news?id=502cff5acd2dd0e1cd89a0d6f8cdca1e2bd2c1ae6f6be62299902380161ffb32"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors despite losses on the day",
    "summary": "Pfizer Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=b760e179a63a0236342dd6df07e99976217c36cb0dc6873af7b6f646fefac990",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734367140,
      "headline": "Pfizer Inc. stock outperforms competitors despite losses on the day",
      "id": 132066917,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=b760e179a63a0236342dd6df07e99976217c36cb0dc6873af7b6f646fefac990"
    }
  },
  {
    "ts": null,
    "headline": "Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs.",
    "summary": "Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs.",
    "url": "https://finnhub.io/api/news?id=f41e72a950ed1b2dd59a424074df6b51376a2e758cb040196c242cef41aab89b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734358920,
      "headline": "Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs.",
      "id": 132064409,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Insurer Stocks Tumble. Trump Echoes Drug Industry Attacks on PBMs.",
      "url": "https://finnhub.io/api/news?id=f41e72a950ed1b2dd59a424074df6b51376a2e758cb040196c242cef41aab89b"
    }
  },
  {
    "ts": null,
    "headline": "Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?",
    "summary": "The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others are coming.",
    "url": "https://finnhub.io/api/news?id=6cb607d103415376d9d07c90278dcd33f958e24cf9dd571a2bc12ffbc7065c56",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734354059,
      "headline": "Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?",
      "id": 132010903,
      "image": "",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others are coming.",
      "url": "https://finnhub.io/api/news?id=6cb607d103415376d9d07c90278dcd33f958e24cf9dd571a2bc12ffbc7065c56"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer (NYSE:PFE) Is Increasing Its Dividend To $0.43",
    "summary": "Pfizer Inc.'s ( NYSE:PFE ) periodic dividend will be increasing on the 7th of March to $0.43, with investors receiving...",
    "url": "https://finnhub.io/api/news?id=abdd7987c844d97344aac3a0b5d763c0c299ccca42034fafa2be78649d2c188e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734345711,
      "headline": "Pfizer (NYSE:PFE) Is Increasing Its Dividend To $0.43",
      "id": 132014639,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/8f018d189c2c443014c49845310ae091",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer Inc.'s ( NYSE:PFE ) periodic dividend will be increasing on the 7th of March to $0.43, with investors receiving...",
      "url": "https://finnhub.io/api/news?id=abdd7987c844d97344aac3a0b5d763c0c299ccca42034fafa2be78649d2c188e"
    }
  },
  {
    "ts": null,
    "headline": "Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030",
    "summary": "Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason.  Drugmakers often see phases of growth as they develop candidates for a high-potential treatment area or as they launch promising new products.  Over time, you can benefit from these periods by buying shares of certain biotech and pharma companies and holding for the long term.",
    "url": "https://finnhub.io/api/news?id=f0a39cb13100310ee4ceab8e3c3544501ca9f7560b8c890e4e0106b8fc0c9210",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734340500,
      "headline": "Prediction: These Could Be the Best-Performing Pharma and Biotech Stocks Through 2030",
      "id": 132009839,
      "image": "https://g.foolcdn.com/editorial/images/801046/gettyimages-1272759382.jpg",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pharmaceutical and biotech stocks often are seen as steady and safe options for investors for one particular reason.  Drugmakers often see phases of growth as they develop candidates for a high-potential treatment area or as they launch promising new products.  Over time, you can benefit from these periods by buying shares of certain biotech and pharma companies and holding for the long term.",
      "url": "https://finnhub.io/api/news?id=f0a39cb13100310ee4ceab8e3c3544501ca9f7560b8c890e4e0106b8fc0c9210"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: Lowest Levels In A Decade Is An Opportunity With A Dividend Yield Exceeding 6.5%",
    "summary": "Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling value play. Explore more details here.",
    "url": "https://finnhub.io/api/news?id=ba38f2fbe24d94d7f457d27641b434249ff11d8fb2c9f0f9da3911ea796eb473",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734339600,
      "headline": "Pfizer: Lowest Levels In A Decade Is An Opportunity With A Dividend Yield Exceeding 6.5%",
      "id": 132011061,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1445810162/image_1445810162.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer's shares have significantly underperformed, but the current valuation and high dividend yield present a compelling value play. Explore more details here.",
      "url": "https://finnhub.io/api/news?id=ba38f2fbe24d94d7f457d27641b434249ff11d8fb2c9f0f9da3911ea796eb473"
    }
  }
]